#Israel #Caesarea #financial results #Cryoablation #IceCure

IceCure Medical to Report Third Quarter 2026 Results

IceCure Medical Ltd., listed on NASDAQ under the ticker ICCM, is set to announce its financial and operational results for the third quarter of 2026 on November 18, 2026. The announcement will take place before the market opens, providing investors and stakeholders with critical insights into the company's performance over the nine months concluding on September 30, 2026.

The report will showcase not only revenue figures but also key developments related to IceCure’s innovative cryoablation technology—a minimally invasive treatment option that effectively destroys tumors through freezing. This technology represents a significant alternative to traditional surgical methods.

Following the release of the financial results, a conference call is scheduled for 10 a.m. EST on the same day. During this call, company executives will delve deeper into the results, sharing insights on operational aspects and addressing questions from investors. Interested parties can join the conference call by dialing US 1-888-407-2553 or from Israel and international locations at +972-3-918-0696. A live webcast will also be available, enabling broader access to the discussion and responses. For those unable to attend live, a recorded version will be made available afterward, ensuring that all stakeholders can review the information at their convenience.

IceCure Medical continues to focus on its flagship product, the ProSense® system, known for its application in treating various types of tumors, including in breast, kidney, bone, and lung cancers. Significantly, the ProSense® system has achieved FDA clearance as the first device authorized for the local treatment of breast cancer for patients aged 70 years or older with specific low-risk tumor profiles. This groundbreaking milestone underlines the company’s commitment to providing safer and more efficient treatment options in the oncology field.

In the lead-up to the financial results announcement, IceCure’s management has indicated optimism regarding the anticipated operational performance and revenue figures. Their confidence stems from ongoing advancements in product development, strategic market positioning, and the potential for future expansions in their global reach.

Furthermore, IceCure continues to address essential factors that could influence their results: the level of marketing and sales activities, relationships with suppliers and partners, regulatory compliance, and the broader economic atmosphere, particularly the volatile conditions in the Middle East, which could affect operations. By actively managing these variables, the company aims to deliver robust financial outcomes and maintain its trajectory of growth.

Moreover, the announcement will also include updates on IceCure's efforts to inform and educate medical professionals regarding its innovative cryoablation technologies, enhancing clinical acceptance and paving the way for improved treatment methodologies.

As the medical technology landscape continues to evolve, IceCure Medical is positioned strategically at the forefront of innovation in minimally invasive treatments. The impending financial results and accompanying conference call are highly anticipated events for investors and clinical stakeholders alike, as they provide an opportunity to assess the company's current position and future potential.

Stay tuned for the official financial report on November 18, and consider joining the conversation during the conference call that will follow, as IceCure Medical shares insights and developments from this quarter's operations.